AIFM2 and cancer: Increased FSP1 levels strongly correlate with poor clinical outcomes, including decreased survival rates and an increased risk of metastasis [68], while the inhibition of FSP1 oxidoreductase activity can effectively delay malignant tumor progression [7,68].